TrialClinical and translational science2024

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.

Ana Liza Andresan Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.